sacituzumab govitecan
gilead sciences
['ascent', 'bcsm', 'congrat', 'tnbc', 'sacituzumab']
important data from #ascent trial. at the final analysis of the trial, sacituzumab govitecan confirmed its meaningful improvement in pfs &amp; os compared with chemo for pretreated tnbc. congrats to all authors! #bcsm #asco22 
Paolo Tarantino, MD, (@PTarantinoMD) #BCSM Researcher from @IEOufficiale, takes over our Twitter today to discuss #ASCO22.